Kenvue Inc.

Kenvue (KVUE) Stock Still Appears 41% Undervalued On Cash Flow

Kenvue has delivered a 16.1% gain over the past year, even as shorter term returns have been softer. This puts fresh focus on whether the current share price lines up with the cash the business can generate over time. With the stock last closing at US$17.22, the question for investors is how much of Kenvue’s future cash flows are already reflected in that tag. The 16.1% return over the past 12 months puts recent buyers in profit and raises the issue of whether that move is fully supported by...

Yahoo Finance · 01/10/2026 · lire l'article ↗

Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes

Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("Acquisition") of Kenvue Inc. (NYSE: KVUE) ("Kenvue"), of an exchange offer (each an "Exchange Offer" and, collectively, the "Exchange Offers") for any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes")

Yahoo Finance · 28/09/2026 · lire l'article ↗

Kenvue Inc's Dividend Analysis

This article first appeared on GuruFocus. Kenvue Inc (NYSE:KVUE) recently announced a total dividend of $0.21 per share, with the ex-dividend date set for 2026-09-21. For income-focused investors, the ex-dividend date is a critical marker: shareholders must own the stock before this date to qualify for the payment.

Yahoo Finance · 21/09/2026 · lire l'article ↗

Kimberly Clark (KMB) Lines Up Assets for $40 Billion Deal Review

Kimberly-Clark (NasdaqGS:KMB) plans to sell assets tied to its planned US$40b acquisition of consumer products group Kenvue. The disposals are aimed at addressing European Union antitrust concerns linked to overlaps in consumer health and personal care brands. Asset sale discussions focus on EU markets where regulators flagged competition issues as part of their ongoing review of the Kenvue deal. Kimberly-Clark's move to sell assets around the US$40b Kenvue deal sits within a broader pattern...

Yahoo Finance · 18/09/2026 · lire l'article ↗

Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

Yahoo Finance · 18/09/2026 · lire l'article ↗

Should Kenvue’s (KVUE) TYLENOL with Naproxen Launch and Dividend Plan Prompt Investor Reassessment?

Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...

Yahoo Finance · 15/09/2026 · lire l'article ↗